KalVista Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Revenue	-	49.08	-	-	-	-
Cost of Revenue	-	3.08	-	-	-	-
Gross Profit	-	46	-	-	-	-
Selling, General & Admin	140	124.66	116.29	54.28	30.6	26.45
Research & Development	53.82	33.37	71.71	86.17	80.28	70.17
Total Operating Expenses	193.81	158.03	188	140.45	110.87	96.61
Operating Income	-177.49	-112.04	-188	-140.45	-110.87	-96.61
Interest Income	7.96	-	6.44	3.9	2.23	1.09
Interest Expense	-13.87	-	-5.79	-	-	-
Other Non-Operating Income (Expense)	8.86	-	7.29	9.91	15.73	13.18
Total Non-Operating Income (Expense)	2.96	-	7.94	13.8	17.96	14.27
Pretax Income	-177.42	-110.56	-180.05	-126.64	-92.91	-82.34
Provision for Income Taxes	6.01	-1.03	3.39	-	-	-
Net Income	-183.43	-109.52	-183.44	-126.64	-92.91	-82.34
Net Income to Common	-183.43	-109.52	-183.44	-126.64	-92.91	-82.34
Shares Outstanding (Basic)	54	51	50	37	28	24
Shares Outstanding (Diluted)	54	51	50	37	28	24
Shares Change (YoY)	8.15%	2.51%	34.98%	31.89%	13.96%	28.17%
EPS (Basic)	-3.42	-2.15	-3.69	-3.44	-3.33	-3.36
EPS (Diluted)	-3.42	-2.15	-3.69	-3.44	-3.33	-3.36
Shares Outstanding	51.24	50.9	49.76	42.52	34.17	24.55
Free Cash Flow	-154.9	0	-153.34	-89.27	-76.46	-79.07
Free Cash Flow Per Share	-2.88	-	-3.09	-2.43	-2.74	-3.23
Gross Margin	-	93.72%	-	-	-	-
Operating Margin	-	-228.28%	-	-	-	-
Profit Margin	-	-223.16%	-	-	-	-
EBITDA	-176.22	-112.04	-187.05	-139.63	-110.15	-96.05
EBIT	-177.49	-112.04	-188	-140.45	-110.87	-96.61
EBIT Margin	-	-228.28%	-	-	-	-
Effective Tax Rate	-3.39%	0.93%	-1.88%	0.00%	0.00%	0.00%

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q